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T  cells can be rendered tumor specific via genetic engineer-ing with a tumor-targeting TCR or a CAR1. TCR- and CAR-engineered T cells have promoted substantial objective clinical 
responses in synovial carcinoma2 and B cell lymphoid malignan-
cies3, respectively. However, although CAR T cells expand in vivo 
in patients with B cell leukemia and can persist up to 24 months 
after infusion4, in solid tumors, the suppressive tumor microenvi-
ronment (TME) usually hinders T cell expansion and persistence 
in multiple ways, such as by inducing checkpoint inhibition5 and 
metabolic starvation6 of T cells.
T cell proliferation requires optimal T cell activation, which inte-
grates signals downstream of the TCR–CD3 complex, engagement 
of co-stimulatory molecules and cytokines7. CAR-based engineering 
provides stimulation through the TCR–CD3 complex and co-stim-
ulatory molecules, whereas TCR-based engineering provides TCR 
engagement without adequate co-stimulation7. The cytokine com-
ponent is a limiting factor for both TCR and CAR engineering strat-
egies. The major pro-proliferative cytokine secreted by engineered 
T cells is IL-2, which may however support the activation and expan-
sion of regulatory T (Treg) cells8, limiting antitumor effects. T cells 
have been engineered to express common γ-chain cytokines such as 
IL-15 in addition to the CAR, which is effective in supporting their 
proliferation and effector function while having only limited effects 
on Treg cells9,10. However, this type of cytokine engineering can lead 
to side effects, as the cytokines are constitutively produced and their 
receptors are expressed by most T cells and natural killer (NK) cells, 
requiring the inclusion of safety switches to contain potential toxic 
effects11–13. Thus, the development of inducible and selective engi-
neering processes supporting T cell expansion and survival within 
the TME remains critical in adoptive T cell therapies in solid tumors 
for both TCR- and CAR-engineered T cells.
Most studies on the use of cytokines to support T cell immuno-
therapies have focused on STAT5-inducing cytokines, such as 
IL-2 and IL-15 (refs. 9,10,14,15). In recent studies, STAT3 signaling 
enhanced CAR T cell effector function in preclinical models16 and 
was associated with better clinical outcome in patients with chronic 
lymphocytic leukemia17. IL-23 is one of the STAT3-activating cyto-
kines and consists of IL-23α p19 and IL-12β p40 subunits18, both 
of which are expressed by activated macrophages and dendritic 
cells19,20. IL-23 is known to promote the proliferation of memory 
T cells and especially T helper type 17 (TH17) cells expressing the 
IL-23 receptor (IL-23R)19,21,22. In particular, skewing CAR T  cells 
toward a TH17 profile by including the ICOS endodomain in the 
CAR construct has been shown to augment antitumor activity23. 
Here we found activation-induced expression of IL-23R and the 
IL-23α p19 subunit in T cells, which allowed us to couple the release 
and activity of IL-23 with T cell activation by supplementing T cells 
with the IL-12β p40 subunit. p40-expressing T cells (p40-Td cells) 
produce IL-23 upon T cell activation, which drives T cell prolifera-
tion and survival. Incorporating p40 in CAR- or TCR-engineered 
T cells enhanced their antitumor activity in xenograft and syngeneic 
mouse models. Furthermore, IL-23 produced by p40-Td cells func-
tions predominantly through an autocrine mechanism, with limited 
effects on bystander cells. Our approach provides robust and selec-
tive proliferative signaling to adoptively transferred tumor-specific 
T cells within the TME.
Results
TCR–CD28 stimulation upregulates the expression of IL-23R in 
T cells. We first evaluated whether IL-23R is expressed in T cells 
expanded ex vivo, following procedures used to generate CAR 
T  cells for clinical use and that expand T  cells phenotypically 
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resembling memory T  cells24 (here collectively called ex-TM cells, 
expressing the CD45RO, CD27 and CD28 phenotypic markers). 
Although ex-TM cells expanded ex vivo at days 10–12 and rested 
from cytokines expressed low levels of IL-23R, stimulation of ex-TM 
cells with anti-CD3/CD28 antibodies upregulated IL-23R expres-
sion at both the mRNA and protein level (Fig. 1a,b). IL-23R expres-
sion in ex-TM cells was functional, as recombinant IL-23 supported 
the expansion of activated ex-TM cells, as previously observed in 
IL-23R+ TH17 cells25, whereas ex-TM cells were irresponsive to IL-23 
in the absence of TCR–CD28 stimulation (Fig. 1c). Furthermore, 
ex-TM cells responding to IL-23 were not polarized to TH17 cells, as 
they showed a CD4+/CD8+ ratio similar to that of untreated T cells 
(Fig. 1d), retained a type I cytokine production profile (Fig. 1e) and 
showed T-bet and RORγT expression similar to that of untreated 
cells26 (Fig. 1f). This lack of TH17 polarization may be attributed to 
the restricted plasticity of ex-TM cells and/or the requirement for 
additional TH17-skewing cytokines such as transforming growth 
factor (TGF)-β, IL-6 and IL-1β, as reported previously27. This selec-
tive activity of IL-23 without skewing toward a pathogenic TH17 
subset prompted us to explore whether the IL-23–IL-23R axis 
could be exploited to support the expansion of activated T  cells 
within the TME.
Functional engineering of the IL-23–IL-23R axis in T  cells. 
Unexpectedly, we observed that ex-TM cells upregulated the IL-23α 
p19 subunit upon TCR stimulation, but not the IL-12β p40 subunit 
(Fig. 1g). The observed inducible expression of both IL-23R and 
the IL-23α p19 subunit in ex-TM cells in response to TCR stimu-
lation offers the unique opportunity to genetically engineer these 
cells with the IL-12β p40 subunit to produce and utilize IL-23 upon 
TCR stimulation. We supplemented ex-TM cells with the p40 sub-
unit via gamma-retroviral transduction to generate p40-Td cells 
(Supplementary Fig. 1a). p40-Td cells, but not empty-vector-trans-
duced T  cells (Ctrl cells), secreted IL-23 upon TCR stimulation 
(Fig. 1h). Of note, p40-Td cells released limited amounts of IL-12 
(~200 pg ml–1 per 106 cells), a cytokine that shares the p40 subunit 
with IL-23 (ref. 22; Fig. 1h). In the absence of TCR–CD28 stimu-
lation, p40-Td and Ctrl cells showed comparable phenotypic char-
acteristics and expansion in culture (Supplementary Fig. 1b–e). In 
contrast, p40-Td cells showed superior expansion upon TCR–CD28 
activation as compared to Ctrl cells (Fig. 1i). This effect could be 
attributed to both increased cell division (Supplementary Fig. 2a,b) 
and reduced apoptosis (Supplementary Fig. 2c). IL-23-mediated 
responses of p40-Td cells required the endogenous IL-23α subunit, 
as knockdown of IL23A mRNA by short hairpin RNA (shRNA) 
abolished both IL-23 production (Fig. 1j) and IL-23-mediated 
T cell expansion (Fig. 1k) in p40-Td cells. Even if p40-Td cells pro-
duced IL-12, the amount produced was low and did not induce 
IL-12 signaling in activated naive CD4+ T  cells (Supplementary 
Fig. 3a,b). Moreover, interferon (IFN)-γ production and TBX21 
gene expression were comparable in activated Ctrl and p40-Td cells 
(Supplementary Fig. 3c,d), confirming the absence of IL-12 signal-
ing in p40-Td cells. Because of this unique activation-inducible 
nature of IL23R and IL23A expression, we further characterized the 
kinetics of their upregulation and IL-23 secretion. We found that 
both gene upregulation and IL-23 secretion were tightly linked to 
T cell activation. IL23R and IL23A expression and IL-23 secretion 
continued to increase with continued T cell stimulation up to day 
5, but declined to baseline levels when T cells were removed from 
stimulation (Supplementary Fig. 4a–c). Furthermore, we also deter-
mined whether T cell activation through native TCR–major histo-
compatibility complex (MHC)/peptide engagement also induced 
IL23R and IL23A expression. We used T cells transduced to express 
a tyrosinase-specific TCR28 and co-cultured them with T2 cells 
pulsed with tyrosinase peptide for 24 h. We found that both IL23R 
and IL23A were induced upon TCR engagement (Supplementary 
Fig. 4d), albeit at a lower level (for IL23A) than was seen following 
stimulation with anti-CD3/CD28 antibodies (Fig. 1g).
Previous studies showed elevated IL23A mRNA levels in tumor 
biopsies, suggesting a potential role for IL-23 in tumor progression, 
Fig. 1 | Il-23 supports the expansion of T cells in an activation-inducible manner. a,b, IL-23r expression at the mrNA level measured by qrT–PCr (a) and 
at the protein level measured by western blot (b) in human T cells activated and expanded ex vivo (ex-TM) at 0, 24 and 48 h after TCr activation. In a, data 
are represented as fold change in expression normalized to 18S rNA and to expression at time 0. Data are shown as individual values and the mean ± s.d. 
(n = 6 in a and n = 5 in b). c, Expansion of ex-TM cells with or without activation with anti-CD3/CD28 antibodies and with or without recombinant IL-23 
(50 ng ml–1). Cell numbers were determined by flow cytometry at day 7. Data are shown as individual values and the mean ± s.d. (n = 4). ***P = 0.0002, 
determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. Tx, treatment; NS, not significant. d, Distribution of CD4+ and CD8+ 
T cells among ex-TM cells activated with anti-CD3/CD28 antibodies in the presence or absence of 50 ng ml–1 recombinant IL-23 at day 7. Data are shown 
as individual values and the mean ± s.d. (n = 4). e, Intracellular detection of IFN-γ and IL-17 in CD4+ and CD8+ T cells among ex-TM cells activated with 
anti-CD3/CD28 antibodies in the presence or absence of 50 ng ml–1 recombinant IL-23 for 7 d. Data are shown as individual values and the mean ± s.d. 
(n = 4). f, relative expression of the TH17 and TH1 transcription factors rOrγT and T-bet, respectively, assessed by qrT–PCr in ex-TM cells activated with 
anti-CD3/CD28 antibodies in the presence or absence of 50 ng ml–1 recombinant IL-23 for 7 d. Data are shown as individual values and the mean ± s.d. 
(n = 4). g, mrNA levels of the IL-23 p19 (IL23A) and p40 (IL12B) subunits in ex-TM cells activated with anti-CD3/CD28 antibodies at 0, 24 and 48 h, 
as determined by qrT–PCr. Data are expressed as fold change in expression, normalized to 18S rNA and to expression at time 0. Data are shown as 
individual values and the mean ± s.d. (n = 4). h, Detection of IL-23 secreted by Ctrl or p40-Td cells activated with anti-CD3/CD28 antibodies for 0, 24 
and 48 h, as measured by ELISA. Data are shown as individual values and the mean ± s.d. (n = 5). ****P < 0.0001, determined by repeated-measures two-
way ANOVA with Sidak’s post hoc test. i, Numeric expansion of Ctrl and p40-Td cells activated with anti-CD3/CD28 antibodies. Data are shown as the 
mean ± s.d. (n = 13). ***P = 0.0006, ****P < 0.0001, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. j, Detection of IL-23 
secreted by activated Ctrl and p40-Td cells co-transduced with vector encoding either control shrNA (sh-Ctrl) or IL23A-targeted shrNA (sh-IL23A). 
Data are shown as individual values and the mean ± s.d. (n = 3). ***P = 0.0002, determined by repeated-measures two-way ANOVA with Sidak’s post 
hoc test. k, Cell counts at day 5 for cells transduced with vector encoding sh-Ctrl or sh-IL23A activated with anti-CD3/CD28 antibodies. Data are shown 
as individual values and the mean ± s.d. (n = 4). **P = 0.0069 for Ctrl cells with sh-Ctrl versus p40-Td cells with sh-Ctrl, **P = 0.0056 for p40-Td cells 
with sh-Ctrl versus p40-Td cells with sh-IL23A, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. l, Expression (transcripts 
per million) of IL23A (left) and IL12B (right) in tumor (red dots) and adjacent normal tissue (green dots) from different patients with cancer plotted using 
TCGA data. Highlighting of tumor types in red indicates higher expression in tumor versus normal tissue, whereas highlighting in green indicates lower 
expression in tumor versus normal tissue. m, Expression of IL23A and IL12B determined by qrT–PCr in breast cancer (BC), colorectal cancer (CrC) and 
pancreatic cancer (PC), together with paired adjacent normal tissue. Data are shown as copies of rNA per 50 ng of rNA (n = 6). The dotted line indicates 
the detection limit of the qrT–PCr assay used (CT > 35). **P = 0.0019, determined by one-way ANOVA with Sidak’s post hoc test. n, Detection of IL-23 by 
ELISA in the supernatant of single-cell suspensions of paired tumor and adjacent normal tissues. Data are shown as pg of IL-23 per 100 μg of supernatant 
protein, with individual values and the mean (n = 6).
especially in colorectal carcinoma (CRC)29,30. However, because 
IL-23 is a heterodimeric protein, both the IL-23α and IL-12β sub-
units must be present in the same cell to produce and release IL-23. 
Analysis of RNA-seq data from The Cancer Genome Atlas (TCGA) 
showed that, whereas the IL23A transcript was upregulated in many 
tumor specimens, the IL12B transcript was barely detectable in 
both tumor and normal tissue specimens (Fig. 1l), predicting an 
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Fig. 2 | TCR activation induces a STAT3 and hypoxia gene signature in p40-Td cells. a, Volcano plots of gene expression before activation (left) and 
5 d after activation (right) with anti-CD3/CD28 antibodies of Ctrl and p40-Td cells (n = 3). Volcano plots were constructed using log2(fold change) and 
–log10(FDr) values for all genes. red dots represent genes with more than a twofold change (up or down) in expression and FDr < 0.01. b, Numbers of
differentially expressed genes before and after stimulation of Ctrl and p40-Td cells. c, Principal-component analysis (PCA) of activated Ctrl and p40-Td 
cells (n = 3). d, GSEA for the expression profiles of activated Ctrl cells as compared to activated p40-Td cells using ‘STAT3 upregulated’ (up) and ‘STAT3 
downregulated’ (down) gene sets and expression heat maps of genes in these gene sets (n = 3). Nominal P values and FDr q values were calculated using 
GSEA software (Broad Institute). e, Top: representative western blots showing Ser727 and Tyr705 phosphorylation of STAT3 in Ctrl and p40-Td cells before 
and 5 d after stimulation with anti-CD3/CD28 antibodies. Bottom: densitometry of phosphorylated STAT3, with data shown as individual values and the 
mean ± s.d. (n = 5). ***P = 0.0001, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. f, qrT–PCr quantification of upregulated 
(red) and downregulated (blue) genes related to the STAT3 pathway. Data were first normalized to 18S rNA and are shown as the mean ± s.d. of the 
log2(fold change) in gene expression for activated Ctrl cells versus p40-Td cells (n = 4). g, GSEA for the expression profiles of activated Ctrl and p40-Td 
cells using the ‘hallmark of hypoxia’ gene set (left) and an expression heat map of genes in the gene set (right) (n = 3). The nominal P value and FDr q value 
were calculated using GSEA software (Broad Institute). h, qrT–PCr quantification of hypoxia-pathway-related genes in activated Ctrl and p40-Td cells. 
Data were first normalized to 18S rNA and then to the expression level in Ctrl cells. Data are shown as individual values and the mean ± s.d. (n = 4).
of the IL-23 subunits at the mRNA and protein level by qPCR and 
ELISA, respectively, in 18 tumor specimens (CRC, pancreatic ductal 
adenocarcinoma (PDAC) and breast cancer). Whereas the IL23A 
gene was upregulated in CRC tumor specimens, IL12B was not 
expressed (Fig. 1m) and IL-23 was absent from most of the super-
natants obtained from CRC specimens (Fig. 1n). Therefore, IL-23 
p40 engineering of T cells may support T cell expansion in a TCR-
activation-dependent manner within the TME, which is deprived 
of IL-23.
Transcriptome analysis of activated p40-Td cells reveals a signa-
ture enriched for STAT3 and hypoxia genes. We performed RNA-
seq analysis to define the molecular pathways involved in p40-Td 
cells. Ctrl cells and p40-Td cells had similar gene expression profiles 
in the absence of TCR stimulation (Fig. 2a). In contrast, after TCR 
activation, p40-Td cells showed a different molecular signature as 
compared to Ctrl cells (Fig. 2a–c), indicating the requirement for 
TCR stimulation to fully exploit the effects of the engineered IL-23–
IL-23R axis in ex-TM cells. Specifically, gene set enrichment analysis 
(GSEA)31 showed a significant enrichment of STAT3-upregulated 
genes in activated p40-Td cells and STAT3-downregulated genes in 
Ctrl cells (Fig. 2d), suggesting elevated STAT3 activity in p40-Td 
cells. The molecular signature was validated by detecting increased 
STAT3 phosphorylation in activated p40-Td cells (Fig. 2e) and 
differential expression of STAT3-regulated genes (SOX2, SOCS3, 
CEBPD, ABCA1, IFIT1, IFIT3, USP18 and CDKN2B) (Fig. 2f). 
Furthermore, we observed an enrichment for genes within the 
hypoxia hallmark gene set in TCR-stimulated p40-Td cells as com-
pared to Ctrl cells (Fig. 2g) and mRNA upregulation of hypoxia-
inducible factors (HIFs) and other HIF target genes (Fig. 2h). 
Overall, these data highlight activation of the STAT3 pathway upon 
TCR activation in p40-Td cells, indicating a dominant role for IL-23 
signaling in these cells.
p40 expression enhances the antitumor activity of CAR T  cells 
in xenograft models of solid tumors. We assessed whether IL-23 
p40 expression in CAR T cells improves their antitumor activity. We 
expressed p40 in CAR T cells (CAR.p40-Td cells) targeting the GD2 
antigen expressed in neuroblastoma (Supplementary Fig. 5a,b). 
CAR.p40-Td cells showed robust expansion (Supplementary Fig. 5c) 
and reduced apoptosis (Supplementary Fig. 5d) when stimulated 
in vitro with an anti-idiotype antibody that cross-links the CAR32, 
as compared to control CAR T  cells (CAR.Ctrl cells). IL-23 was 
only detected in activated CAR.p40-Td cells, whereas IL-2 secre-
tion remained unchanged (Supplementary Fig. 5e). The antitumor 
effects of CAR T cells in vitro were assessed by repetitive tumor co-
culture assays in which human neuroblastoma cell lines (LAN-1 and 
CHLA-255) were used at a high tumor to T cell ratio (Supplementary 
Fig. 6a). In this stress culture condition test, CAR.Ctrl cells failed 
to control tumor growth after the first or second round of co-cul-
ture, whereas CAR.p40-Td cells remained effective (Fig. 3a,b). In 
parallel, the number of CAR.Ctrl cells was gradually reduced after 
each round of co-culture, whereas CAR.p40-Td cells persisted and 
retained CAR expression (Fig. 3c,d and Supplementary Fig. 6b). In 
addition to enhanced proliferation, CAR.p40-Td cells showed supe-
rior effector function at the individual cell level. Specifically, CAR.
p40-Td cells expressed higher levels (as evaluated by percentage 
and mean fluorescence intensity (MFI)) of the lytic enzyme gran-
zyme B (Fig. 3e) and reduced expression of the exhaustion markers 
PD-1 and CD101 (ref. 33; Fig. 3f), as compared to CAR.Ctrl cells. 
In addition, after repeated stimulation, CAR.Ctrl cells exhibited a 
progressive reduction in the percentage of T cells producing IFN-γ 
and TNF-α, an indicator of functional exhaustion34, whereas CAR.
p40-Td cells continued to produce IFN-γ and TNF-α (Fig. 3g). In 
a metastatic neuroblastoma model in NOD-SCID-IL-2Rnull (NSG) 
mice, treated with suboptimal doses (2 × 106 cells) of CAR T cells, 
CAR.p40-Td cells promoted enhanced tumor control and improved 
survival as compared to CAR.Ctrl cells (Fig. 3h–k). In line with 
this, CAR.p40-Td cells showed superior initial expansion (day 10) 
in vivo in peripheral blood, spleen and liver (Fig. 3l) and prolonged 
persistence in the same organs at the time that mice were killed 
(Fig. 3m). When a higher dose (4 × 106 cells) of CAR T  cells was 
used in tumor-bearing mice, both CAR.Ctrl and CAR.p40-Td cells 
promoted tumor regression (Fig. 3n–p), but only mice receiving 
CAR.p40-Td cells were protected from tumor re-challenge 4 weeks 
after T cell treatment (Fig. 3n–p). Notably, the enhanced antitumor 
activity provided by p40 overexpression was not restricted to CAR 
T cells cultured ex vivo with IL-7 and IL-15 (Supplementary Fig. 6c) 
Fig. 3 | p40 expression enhances the antitumor activity of CAR T cells in a neuroblastoma model. a,b, Counts of LAN-1 (a) and CHLA-255 (b) 
neuroblastoma tumor cells after each round of repetitive co-culture (rounds 1–3, r1–r3) with control T cells (Ctrl), GD2-specific CAr T cells (CAr.Ctrl) or 
GD2-specific CAr T cells coexpressing p40 (CAr.p40-Td). Data are shown as individual values and the mean ± s.d. (n = 8). ****P < 0.0001, determined by 
repeated-measures two-way ANOVA with Sidak’s post hoc test. c,d, T cell counts after each round of repetitive co-culture illustrated in a and b. Data are 
shown as individual values and the mean ± s.d. (n = 8). *P = 0.03 for LAN-1 round 2, **P = 0.0049 for LAN-1 round 3, ***P = 0.0003 for CHLA-255 round 2, 
**P = 0.0091 for CHLA-255 round 3, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. e, Intracellular staining for granzyme 
B of CAr.Ctrl and CAr.p40-Td cells at the end of round 1. Data are shown as individual values and the mean ± s.d. (n = 3). **P = 0.0052, determined 
by two-sided paired t-test. f, Expression of PD-1 and CD101 in CAr.Ctrl and CAr.p40-Td cells after rounds 1 and 2 of repetitive co-culture with LAN-1 
tumor cells. Data are shown as individual values and the mean ± s.d. (n = 3). **P = 0.0014 for PD-1 round 2, *P = 0.0365 for CD101 round 2, determined 
by repeated-measures two-way ANOVA with Sidak’s post hoc test. AU, arbitrary units. g, Intracellular staining for IFN-γ and TNF-α of CAr.Ctrl and CAr.
p40-Td cells at the end of rounds 1 and 2 of co-culture with LAN-1 tumor cells. Data are shown as individual values and the mean ± s.d. (n = 3). **P = 0.002 
for IFN-γ+ cells round 1, *P = 0.0409 for IFN-γ+TNF-α+ cells round 1, ****P < 0.0001 for IFN-γ+ cells round 2, **P = 0.009 for IFN-γ+TNF-α+ cells round 
2, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. h, Schematic of the metastatic neuroblastoma xenograft model; i.v., 
intravenous. i, representative tumor bioluminescence from two independent experiments. IVIS, imaging (using IVIS Lumina II in vivo imaging system). 
j, Kinetics of tumor bioluminescence from two independent experiments (n = 8 mice for the Ctrl group, n = 9 mice per group for the CAr.Ctrl and CAr.
p40-Td groups). Thick lines delineate mean fold change over time, while thin lines show data for each individual mouse. k, Kaplan–Meier survival curves 
summarizing two independent experiments (n = 8 mice per group). ****P < 0.0001. l, Frequency of human CD3+CD45+ cells in blood, spleen and liver 
collected 10 d after T cell infusion. Data are shown as individual values and the mean (n = 5 mice per group) and are representative of two experiments. 
***P = 0.0006 for blood, ****P < 0.0001 for liver, ***P = 0.0007 for spleen, determined by one-way ANOVA with Sidak’s post hoc test. m, Frequency 
of human CD3+CD45+ cells in blood, spleen and liver collected at the time that mice were killed (median collection time: 18, 22 and 52 days post T cell 
infusion for the Ctrl, CAr.Ctrl and CAr.p40-Td groups, respectively). Data are shown as individual values and the mean (n = 5 mice per group) and are 
representative of two experiments. *P = 0.0132 for blood, **P < 0.0067 for liver, **P = 0.0071 for spleen, determined by one-way ANOVA with Sidak’s 
post hoc test. n, Schematic of the metastatic neuroblastoma xenograft model and tumor re-challenge. o, representative tumor bioluminescence from two 
independent experiments. p, Kinetics of tumor bioluminescence from two independent experiments (n = 6 mice for the Ctrl group, n = 7 mice per group for 
the CAr.Ctrl and CAr.p40-Td groups). Thick lines delineate mean fold change over time, while thin lines show data for each individual mouse.
nor to CAR T cells encoding the CD28 co-stimulatory endodomain 
(Supplementary Fig. 7). Moreover, the enhanced antitumor activity 
of CAR.p40-Td cells was confirmed in a PDAC model using CAR 
T cells targeting the B7-H3 antigen (Supplementary Fig. 8)35. CAR.
p40-Td cells showed superior antitumor effects and better persis-
tence in stressed co-culture conditions against the human PDAC 
cell line BXPC-3 in comparison to CAR.Ctrl cells (Fig. 4a,b). 
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line that constitutively expresses high levels of PD-L1 and is more 
resistant to CAR T cell effects35, CAR.p40-Td cells showed superior 
antitumor effects and better persistence when compared to CAR.
Ctrl cells (Fig. 4c–g and Supplementary Fig. 8b,c). Therefore, p40 
engineering of CAR T cells promotes antitumor activity, sustaining 
T cell persistence and expansion.
Incorporation of p40 in mouse T cells promotes local effects of 
IL-23 in syngeneic tumor models of melanoma and pancreatic 
cancer. To evaluate the effects of IL-23 in immune-replete mice, we 
implemented syngeneic tumor models. We first confirmed that Il23r 
and Il23a, but not Il12b, were inducible in ex vivo-activated mouse 
T  cells that resembled human ex-TM cells generated for adoptive 
T cell transfer (Fig. 5a,b). Recapitulating the observations in human 
ex-TM cells, gene transfer of the mouse Il12b gene into mouse 
T cells resulted in activation-inducible IL-23 secretion (Fig. 5c) and 
enhanced T  cell expansion (Fig. 5d) in  vitro upon TCR stimula-
tion. We tested the antitumor effects of mouse T cells expressing the 
mouse p40 subunit using the B16-OVA melanoma mouse model 
and adoptive transfer of ex vivo-expanded OT-1 T cells (Fig. 5e). 
When B16-OVA-bearing mice were treated with suboptimal doses 
(1 × 106 cells per mouse) of OT-1 T cells, OT-1 T cells engineered 
to express p40 (OT-1-mp40-Td cells) showed superior tumor con-
trol as compared to OT-1 T  cells transduced with empty vector 
(OT-1-EV cells) (Fig. 5f, left). Treatment with a higher dose (2 × 106 
cells per mouse) of OT-1-mp40-Td cells resulted in sustained tumor 
control up to 30 d after tumor inoculation (Fig. 5f, right). Notably, 
IL-23 was detected only in supernatant obtained from the tumor 
and not in the serum of mice treated with OT-1-mp40-Td cells 
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Fig. 4 | p40 expression enhances the antitumor activity of CAR T cells in a pancreatic cancer model. a, Counts of pancreatic cancer (BXPC-3) cells after 
each round of repetitive co-culture with Ctrl T cells, B7-H3-specific CAr T cells (CAr.Ctrl) or B7-H3-specific CAr T cells coexpressing p40 (CAr.p40-Td) 
at a T cell to tumor cell ratio of 1:2 (left) or 1:5 (right). Data are shown as individual values and the mean ± s.d. (n = 6). ***P = 0.0003, ****P < 0.0001, 
determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. b, T cell counts after each round of repetitive co-culture in a. Data are 
shown as individual values and the mean ± s.d. (n = 6). *P = 0.0195 for round 2 with a 1:2 ratio, *P = 0.021 for round 3 with a 1:2 ratio, **P = 0.0024 for 
round 2 with a 1:5 ratio, ****P < 0.0001, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. c, Schematic of the orthotopic 
pancreatic cancer model. d, representative tumor bioluminescence from two independent experiments (n = 8 mice per group). e, Kinetics of tumor 
bioluminescence from two independent experiments (n = 8 mice per group). Thick lines delineate mean fold change over time, while thin lines show data 
for each individual mouse. ****P < 0.0001. f, Kaplan–Meier survival analysis for two independent experiments (n = 8 mice per group). ****P < 0.0001.  
g, Frequency of human CD3+CD45+ cells in blood, spleen and pancreas collected from mice at day 60 after T cell infusion. Data are shown as individual 
values and the mean (n = 7 mice per group from two independent experiments). **P = 0.0017 for blood, **P = 0.00065 for spleen, **P = 0.0014 for 
pancreas, determined by two-sided unpaired Student’s t-test.
cells, we observed a higher percentage of CD8+ OT-1 T cells within 
the tumor, but not in the blood, spleen or tumor draining lymph 
node (dLN), where the frequency of OT-1 T cells was similar to that 
in mice receiving control OT-1-EV T cells (Fig. 5h). Furthermore, 
no alteration in the composition of CD4+ and CD8+ T  cells, B 
cells, NK cells or myeloid cells was observed in the blood, spleen, 
tumor or dLN (Fig. 5i). To further validate our approach using CAR 
T cells, we used our previously established syngeneic PDAC model 
and B7-H3-specific CAR T cells35 (Fig. 5j). Specifically, the KPC-
4662 PDAC cell line expressing mouse B7-H3 was orthotopically 
engrafted into C57BL/6 mice. As previously reported, the engrafted 
tumors hosted a comprehensive immune microenvironment that 
included B cells, Treg cells, macrophages, Gr1+ myeloid-derived 
suppressor cells and tumor-associated fibroblasts (Supplementary 
Fig. 9)36–38. Upon engraftment, mice were treated with mouse 
T cells expressing the B7-H3-specific CAR (Supplementary Fig. 10) 
and transduced with either empty vector (B7-H3.CAR.EV) or 
vector encoding the mouse p40 subunit (B7-H3.CAR.mp40-Td). 
Mice treated with B7-H3.CAR.mp40-Td cells showed significantly 
better tumor control than mice treated with B7-H3.CAR.EV cells 
(Fig. 5k). Collectively, we demonstrated that p40 engineering in 
mouse T  cells expressing a tumor-specific TCR or CAR exerts a 
local effect that enhances antitumor activity without disturbance of 
global immune composition.
CAR T cells equipped with p40 show superior antitumor efficacy 
and safety in comparison to CAR T cells engineered with IL-18 
or IL-15. Incorporation of cytokines such as IL-18 (refs. 39–41) and 
IL-15 (ref. 42) into CAR constructs improves the antitumor activity 
of CAR T cells. Therefore, we performed a side-by-side comparison 
between CAR.p40-Td cells and CAR T cells engineered with either 
IL-18 (CAR.IL18-Td) or IL-15 (CAR.IL15-Td). CAR.p40-Td cells 
showed the most prominent cell expansion following CAR stimu-
lation in vitro (Supplementary Fig. 11a), while CAR.IL15-Td cells 
showed some level of activation-independent cell proliferation, as 
previously described42 (Supplementary Fig. 11b). CAR.p40-Td cells 
also showed more consistent and prolonged tumor control in repeti-
tive co-culture assays (Supplementary Fig. 11c). In the metastatic 
neuroblastoma model in immunodeficient mice, using low CAR 
T cell doses (2 × 106 cells), CAR.p40-Td cells showed better antitu-
mor control without any apparent side effects, as compared to mice 
treated with CAR.IL18-Td or CAR.IL15-Td cells, which, despite 
showing antitumor activity, caused weight loss (Supplementary 
Figs. 12 and 13). We further corroborated the superior antitumor 
activity of p40 versus IL-18 and IL-15 in the B16-OVA–OT-1 immu-
nocompetent mouse model (Supplementary Fig. 14). Collectively, 
tumor-specific T cells equipped with p40 outperformed tumor-spe-
cific T cells coexpressing either IL-18 or IL-15 with respect to both 
antitumor activity and safety.
Engineered IL-23 functions predominantly through an autocrine 
mode of action. To better characterize the mode of action of IL-23 
in p40-expressing T cells, we mixed p40-Td cells, which were tagged 
with a truncated form of NGFR (NGFR+)43, in  vitro with control 
T cells tagged with a truncated form of CD19 (ΔCD19-Td)44 at a 
1:1 ratio and stimulated the mixed cells with anti-CD3/CD28 anti-
bodies (Fig. 6a). Despite the two cell types having the same culture 
medium containing IL-23, expressing comparable levels of IL-23R 
(Fig. 6b) and being equally responsive to exogenously supplemented 
IL-23 (Supplementary Fig. 15a), p40-Td cells expanded more than 
ΔCD19-Td cells (Fig. 6c,d). Similarly, in multiple-round co-culture 
assays with mixed CAR.p40-Td cells and control CAR.ΔCD19-Td 
cells, CAR.p40-Td cells preferentially expanded in response 
to tumor cells as compared to control CAR T  cells (Fig. 6e,f). 
To further study the self-beneficial effects of IL-23 in p40-Td cells, 
we evaluated whether IL-23 produced by p40-Td cells preferen-
tially bound to the IL-23R expressed by p40-Td cells rather than 
the IL-23R expressed by bystander cells. We generated a p40–GFP 
fusion protein that allowed us to track the location of IL-23 (p19 
and p40–GFP heterodimer) produced by T cells (Fig. 6g). We co-
cultured T cells transduced to express p40–GFP (p40-GFP-Td cells) 
with ΔCD19-tagged control T cells and measured cell-surface bind-
ing of the p40–GFP fusion protein using an anti-GFP antibody con-
jugated to a far-red fluorochrome, to discriminate true extracellular 
binding of the p40–GFP protein from the GFP signal within cells 
(Fig. 6h). Upon TCR stimulation, both flow cytometry (Fig. 6i) and 
confocal microscopy (Fig. 6j) showed abundant GFP binding on the 
cell surface of p40-GFP-Td cells, but not on ΔCD19-Td cells, even 
when p19 and p40–GFP heterodimers could readily be detected in 
the culture medium (Fig. 6g). These data confirm the preferential 
binding of IL-23 to the T cells producing it. One possible explana-
tion for the preferential binding of IL-23 to IL-23-producing T cells 
is that IL-23 is captured by IL-23R on p40-Td cells before its diffu-
sion. To test this hypothesis, we used soluble recombinant human 
IL-23R (rhIL-23R) that binds IL-23, preventing its engagement 
with the IL-23R expressed by T  cells (Supplementary Fig. 15b). 
Fig. 5 | p40 expression enhances the antitumor activity of T cells in syngeneic tumor models. a,b, Expression of Il23a and Il12b (a) and of Il23r (b) as 
determined by qrT–PCr in ex vivo-activated and expanded mouse splenic T cells after re-stimulation with anti-CD3/CD28 antibodies for 0, 24 and 48 h. 
Data are represented as the fold change in gene expression, normalized to the housekeeping gene Cd3e and to the value at time 0. Data are shown as 
individual values and the mean ± s.d. (n = 4). c, Measurement of mouse IL-23 released by mouse splenic T cells transduced with either empty vector (EV) 
or vector encoding mouse Il12b (mp40-Td) and re-stimulated with anti-CD3/CD28 antibodies for 0, 24 and 48 h. Data are shown as individual values 
and the mean ± s.d. (n = 8). **P = 0.0055, ****P < 0.0001. d, Cell counts of EV and mp40-Td mouse T cells at days 1, 3 and 5 after re-stimulation with 
anti-CD3/CD28 antibodies. Data are shown as the mean ± s.d. (n = 3). ****P < 0.0001, determined by repeated-measures two-way ANOVA with Sidak’s 
post hoc test. e, Schematic of the syngeneic B16-OVA melanoma model; s.c., subcutaneous. f, Measurement of tumor volume after tumor engraftment. 
Data are shown as the mean ± s.d. of two independent experiments. For experiments with 1 × 106 T cells, n = 5 mice per group for wild-type (WT) cells  
and n = 8 mice per group for OT-1-EV and OT-1-mp40-Td cells. For experiments with 2 × 106 T cells, n = 6 mice per group for WT and OT-1-EV cells and 
n = 7 mice per group for OT-1-mp40-Td cells. *P = 0.0182, ***P = 0.0007, ****P < 0.0001, determined by two-way ANOVA with Sidak’s post hoc test.  
g, Detection of mouse IL-23 in serum and tumor supernatant collected 14 d after T cell infusion. Data are shown as individual values and the mean (n = 5 
mice per group for serum and n = 7 mice per group for tumor supernatant). h, Frequency of OT-1 TCr+ (Vα2+Vβ5+) cells among CD8+ T cells in the tissues 
collected from treated mice. Data are shown as the mean ± s.d. (n = 5 mice per group). ****P < 0.0001, determined by two-way ANOVA with Sidak’s post 
hoc test. i, Immune composition of peripheral blood, spleen, dLN and tumor at the time that mice were killed. Data are shown as individual values and the 
mean ± s.d. of two independent experiments (n = 9 mice per group). j, Schematic of the syngeneic PDAC orthotopic model. Mouse cell line KPC-4662, 
engineered to express mouse B7-H3 (KPC-mB7-H3), was implanted (0.1 × 106 cells per mouse) into the pancreas of 6-week-old C57BL/6 mice. Eighteen 
days after tumor cell implantation, mice were irradiated with 400 cGy and 3 d later were infused intravenously with syngeneic B7-H3.CAr.EV cells (1 × 107 
cells per mouse) or B7-H3.CAr.mp40-Td cells (1 × 107 cells per mouse). Tumor growth was monitored by ultrasound. k, Summary of the mean fold change 
(compared to day 0) in tumor volume from two independent experiments (n = 8 mice per group). ****P < 0.0001, determined by two-way ANOVA with 
Sidak’s post hoc test for comparison of B7-H3.CAr.EV cells with B7-H3.CAr.mp40-Td cells at day 42.
We found that, even when the IL-23 in diffusion was fully seques-
tered, the cell-surface binding of p40–GFP to p40-Td cells remained 
unchanged, as measured by both flow cytometry (Fig. 6k) and con-
focal microscopy (Fig. 6l). In addition, rhIL-23R did not hamper 
IL-23-mediated expansion of p40-Td cells (Fig. 6m), suggesting that 
free IL-23 does not contribute to the binding or function of IL-23 in 
p40-Td cells. Collectively, these data showed an autocrine mode of 
action of IL-23 that has limited effects on bystander cells.
Discussion
In this study, we have demonstrated that providing the p40 
subunit of IL-23 to tumor-specific T  cells is sufficient to cause 
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the production and release of IL-23. Furthermore, IL-23 exerts its 
function exclusively through activated T  cells because both 
IL-23 production and IL-23R expression occur following T  cell 
activation. This tightly regulated IL-23–IL-23R-engineered 
pathway is further controlled by an autocrine mode of action of 
the secreted IL-23 that prevents cytokine usage by other bystander 
immune cells.
The role of IL-23 in tumor cell growth remains controversial. 
Studies have shown that low amounts of endogenous IL-23 pro-
duced by tumor-associated macrophages, dendritic cells or tumor 
cells may promote inflammation, favoring early tumor initiation 
and progression21,29,30,45. IL-23 was also reported to promote metas-
tasis in some CRC models46. On the contrary, high levels of IL-23, 
obtained either through IL-23 engineering of tumor cells or admin-
istration of recombinant IL-23, had antitumor effects47,48. Our data 
in multiple mouse models demonstrate the antitumor benefit of 
IL-23 when this cytokine is produced by engineered tumor-spe-
cific T  cells, while no obvious side effects are exhibited, as com-
pared to other previously reported cytokine engineering strategies. 
Furthermore, we observed that IL-23 by itself is not sufficient to 
promote the differentiation of ex vivo-generated tumor-specific 
T cells into IL-17-producing cells, the main culprit for promotion of 
carcinogenesis in IL-23-sensitive tumors such as CRC30.
We have made the unexpected observation that the IL23A (p19) 
gene, but not the IL12B (p40) gene, is expressed in ex vivo-generated 
tumor-specific T cells when these cells are activated via engagement 
of either the endogenous TCR or an inserted CAR. Furthermore, the 
observed activation-dependent p19 expression is conserved in both 
mouse and human T cells and is especially pronounced in mouse 
T cells, where p19 expression is upregulated by more than 10,000-
fold upon activation. Notably, p19 is sufficiently expressed to allow 
functional production and release of IL-23 if the p40 subunit is pro-
vided. To our knowledge, no specific functions have been attributed 
to the single p19 subunit. It is generally accepted that IL-23 in its 
heterodimeric form is assembled intracellularly and that p19 is not 
secreted as an independent protein nor in association with proteins 
other than p40 (refs. 18,49). However, one study showed that human 
gastric carcinoma cells can secrete p19 in the absence of p40 sub-
unit50, which implies that the subunit may have IL-23-independent 
functions. Although our data suggest that IL23A knockdown does 
not have detrimental effects in T cells, a more exhaustive assessment 
of the function of p19 in T cells is warranted.
The p40 engineering we propose has multiple potential advan-
tages. While a milieu of cytokines supporting T  cell survival and 
proliferation is critical to obtaining antitumor effects after adoptive 
T  cell therapies, the clinical experience demonstrates that toxic 
effects secondary to systemic and uncontrolled cytokine spread 
occur. The proposed p40 engineering restricts cytokine spread 
because IL-23 is released exclusively upon T cell activation within 
the TME. In fact, even if the p40 subunit is constitutively expressed 
in engineered T cells, IL-23 is only assembled when the p19 sub-
unit is upregulated in response to T  cell activation. Upon secre-
tion within the TME, γ-chain cytokines can be used by a variety 
of immune cells that express the γ-chain receptor, which either 
amplifies or attenuates T  cell-mediated immune responses51,52. In 
contrast, IL-23R expression is much more restricted and T  cells 
releasing IL-23 express high levels of IL-23R. A similar scenario was 
previously modeled in the context of IL-2 and Treg cells, showing 
preferential capture of the cytokine by the cells producing it, thereby 
limiting diffusion and bystander effects53,54. Indeed, IL-23 released 
by p40-enginiered T  cells is preferentially bound to the IL-23R 
expressed by the same cells. This model for IL-23 was supported 
by our data showing that sequestering of soluble IL-23 by soluble 
IL-23R did not reduce IL-23 binding and activity in p40-Td cells. 
Therefore, this autocrine mode of action of IL-23 further supports 
the improved specificity and safety of p40 engineering in tumor-
specific T cells.
The generation of autologous cellular T cell products in patients 
with cancer has the caveat that T cells may be functionally impaired 
owing to age, specific disease or previous therapies the patient 
may have received. It was recently shown in patients with chronic 
lymphocytic leukemia, which is characterized by the presence of 
dysfunctional T cells, that activation of the STAT3 signaling path-
way correlated with better performance of CAR T cells generated 
ex vivo16,17. Our data support the beneficial role of STAT3-associated 
pathways, which are induced by IL-23 through p40 engineering. 
Downstream of STAT3 signaling, we also observed enrichment of 
hypoxia-related genes in p40-Td cells. We speculate that this effect 
is possibly due to cooperative transactivation by STAT3 and HIF 
transcription factors55,56. Furthermore, this molecular profile resem-
bles our previously described hypoxia signature in effector memory 
T  cells, likely contributing to the proliferative and antiapoptotic 
functions of p40 (ref. 24).
In summary, we describe a new strategy to incorporate a 
highly regulated cytokine signaling pathway into tumor-specific 
T  cells that improves their efficacy. Our approach has substantial 
translational potential considering that it can be used for both 
CAR- and TCR-engineered T cells, as both TCR and CAR activation 
Fig. 6 | engineered Il-23 functions predominantly through an autocrine mode of action. a, Schematics of the co-activation experiment with p40-Td and 
ΔCD19-Td cells. b, representative western blot showing the expression of IL-23r in ΔCD19-Td and p40-Td cells at days 1 and 3 after activation (n = 3).  
c, representative plots of NGFr+ (p40-Td) cells and CD19+ (bystander) cells at days 0 and 5 after activation. Data are representative of five independent 
experiments. d, Cell number and percentage of NGFr+ and CD19+ cells 5 d after activation. Data are shown as individual values and the mean ± s.d. (n = 5). 
Dotted lines indicate starting cell number or percentage. ****P < 0.0001, ***P = 0.0008, determined by two-sided paired Student’s t-test. e, Schematic 
of the sequential co-culture of GD2-specific CAr T cells coexpressing either ΔCD19 (CAr.ΔCD19-Td) or p40 (CAr.p40-Td) with the LAN-1 tumor cell 
line. f, Percentages of NGFr+ and CD19+ CAr T cells detected at the end of the first and second rounds of co-culture. Data are shown as individual values 
and the mean ± s.d. (n = 6). ****P < 0.0001, determined by repeated-measures two-way ANOVA with Sidak’s post hoc test. g, Flow plot illustrating the 
coexpression of NGFr and GFP (left) and detection of IL-23 in the supernatant (right) for T cells transduced with a vector encoding the p40–GFP fusion 
protein. Data are shown as individual values and the mean ± s.d. (n = 4). h, Schematics and staining procedure for the co-activation experiment with cells 
expressing p40–GFP and ΔCD19-Td cells. i, representative flow histograms showing binding of p40–GFP protein on the cell surface of CD19+ and NGFr+ 
T cells. Data are shown as individual values and the mean ± s.d. (n = 5). ***P = 0.0003, determined by two-sided paired Student’s t-test. j, representative 
confocal microscopy imaging showing binding of p40–GFP protein on the cell surface of CD19+ and NGFr+ cells, representative of five independent 
experiments (left), and quantification of the fluorescence intensity of the cell-surface GFP signal for CD19+ and NGFr+ cells (right). Data are shown as 
individual values and the mean ± s.d. (n = 49 cells for CD19+ cells, n = 44 cells for NGFr+ cells). ****P < 0.0001, determined by two-sided paired Student’s 
t-test. k,l, Cell-surface binding of p40–GFP on p40-GFP-Td cells in the absence or presence of soluble rhIL-23r as determined by flow cytometry (k) and 
confocal microscopy (l). Data are shown as individual values and the mean ± s.d. (n = 5 independent experiments for k, n = 25 and 23 cells analyzed for 
the no treatment and rhIL-23r groups, respectively, in l). m, Number of Ctrl and p40-Td T cells 5 d after activation with anti-CD3/CD28 antibodies in 
the presence or absence of soluble rhIL-23r. Data are shown as individual values and the mean ± s.d. (n = 6). ***P = 0.0006, determined by repeated-
measures two-way ANOVA with Sidak’s post hoc test.
allow upregulation of IL-23R and the p19 subunit, and the endog-
enous p19 subunit can be coupled with the ectopically expressed 
p40 subunit.
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Methods
Cell lines. The CHLA-255 neuroblastoma cell line was provided by L.S. Metelitsa 
of Baylor College of Medicine57, and the LAN-1 cell line was obtained from M. 
Brenner at Baylor College of Medicine58. Human PDAC cell line BXPC-3 and 
T2 cells were purchased from the American Type Culture Collection (ATCC). 
Tumor cell lines were transduced to express eGFP and firefly luciferase (Ffluc) for 
co-culture and mouse experiments, respectively, as previously described59. Human 
tumor cell lines in this study (LAN-1, CHLA-255, BXPC-3, T2) were maintained 
in complete RPMI medium (500 ml RPMI-1640 (Gibco) supplemented with 10% 
FBS (Germini), 2 mM GlutaMAX (Gibco), 100 U ml–1 penicillin and 100 μg ml–1 
streptomycin (Gibco)). Mouse melanoma B16-OVA cells were provided by B. 
Vincent at the University of North Carolina at Chapel Hill and were maintained 
in complete RPMI medium with addition of 100 μM β-mercaptoethanol (Fisher) 
and 500 μg ml–1 G418 (Gibco) to maintain OVA expression. Mouse PDAC cell line 
KPC-mB7-H3 was established and described previously35 and was maintained in 
complete RPMI medium. All cell lines were routinely tested for mycoplasma and 
for cell-surface expression of target antigens.
Plasmid construction and retrovirus production. Full-length human IL12B 
(accession NM_002187.3), human IL18 (accession NM_001562.4), mouse 
Il12b (accession NM_001303244.1), mouse Il18 (accession NM_008360.2) and 
mouse Il15 (accession NM_008357.2) were amplified by PCR from cDNA clones 
purchased from Origene and cloned into the retroviral vector SFG. Human IL12B 
and IL18 were then subcloned into SFG vector containing an internal ribosomal 
entry site (IRES) and a truncated NGFR selectable marker (p40(i)NGFR; 
Supplementary Fig. 1a). As control, we used an empty vector containing the IRES 
and the NGFR gene (Ctrl(i)NGFR). Mouse Il12b, Il18 and Il15 were subcloned 
into SFG vector containing an IRES and a GFP marker, using empty vector with 
IRES and GFP as the control. The shRNA construct for IL23A was purchased from 
Origene (HuSH-29TM), and the promoter and shRNA sequences were amplified 
by PCR and cloned into SFG vector with a reverse (3′-to-5′) orientation. The p40–
GFP fusion protein was generated by fusing the coding region of IL12B (amino 
acids 1–328) to the GFP gene by fusion PCR and was cloned into the SFG(i)NGFR 
vector. The CAR constructs used in this study were described previously42,60,61.
Retroviral supernatants used for transduction were prepared as previously 
described62. To transduce human T cells, retrovirus with RD114 envelope was used. 
For mouse T cell transduction, retrovirus was generated using packaging vector 
encoding Eco envelope protein.
Transduction and expansion of human T cells. Buffy coats from healthy donors 
were purchased from the Gulf Coast Regional Blood Center (Houston). Peripheral 
blood mononuclear cells (PBMCs) isolated with Lymphoprep density separation 
(Fresenius Kabi Norge) were activated on plates coated with 1 μg ml–1 anti-CD3 
(Miltenyi Biotec) and 1 μg ml–1 anti-CD28 (BD Biosciences) agonistic monoclonal 
antibodies. On day 2, T lymphocytes were transduced with retroviral supernatants 
using retronectin-coated plates (Takara Bio). To generate CAR.Ctrl, CAR.p40-
Td and CAR.IL18-Td cells, double transduction was performed sequentially 
(day 2, CAR transduction; day 3, Ctrl(i)NGFR, p40(i)NGFR or IL18(i)NGFR 
transduction). On day 4, transduced T cells were collected from retronectin-
coated plates and expanded in complete T cell medium (45% RPMI-1640 and 
45% Click’s medium (Irvine Scientific) supplemented with 10% FBS (Hyclone), 
2 mM GlutaMAX, 100 U ml–1 penicillin and 100 μg ml–1 streptomycin) with IL-7 
(10 ng ml–1; PeproTech) and IL-15 (5 ng ml–1; PeproTech), changing the medium 
every 2–3 d (ref. 63). On days 10–14 after transduction, cells were collected for 
in vitro and in vivo experiments. T cells were cultured in IL-7- and IL-15-depleted 
medium for 1 d before being used for in vitro assays.
Preparation of ex vivo-expanded mouse T cells. Mouse T cells were isolated 
using the Mojosort T cell isolation kit (BioLegend) from splenocytes obtained 
from C57BL/6J or C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) mice acquired from 
the Jackson Laboratory or in-house breeding. T cells were then stimulated on 
plates coated with 1 μg ml–1 anti-mouse CD3 (eBioscience) and 1 μg ml–1 anti-
mouse CD28 (eBioscience) monoclonal antibodies for 48 h. Activated mouse T 
lymphocytes were transduced with retroviral supernatant using retronectin-coated 
plates with the same protocol used to transduce human T cells. After removal from 
the retronectin-coated plates, T cells were expanded in complete medium (RPMI-
1640 (Gibco) supplemented with 10% FBS (Hyclone), 2 mM GlutaMAX, 100 μM 
β-mercaptoethanol, 100 U ml–1 penicillin and 100 μg ml–1 streptomycin) with IL-7 
(10 ng ml–1) and IL-15 (5 ng ml–1), changing the medium every 2 d. On day 5, T cells 
were collected and used for subsequent assays.
Quantitative real-time PCR. RNA was extracted from cells with the RNeasy Plus 
kit (Qiagen), quantified by NanoDrop or Qubit and reverse transcribed into cDNA 
using Superscript VILO (Thermo). Quantitative real-time PCR was performed 
using the QuantStudio 6 Flex real-time PCR system (Thermo). The TaqMan 
system was used in most assays except for the validation of RNA-seq analysis 
(STAT3-regulated and hypoxia pathway genes), which used the SYBR Green 
system. For comparison of gene expression in human T cells, 18S RNA was used as 
a control for normalization. For assays in mouse T cells, Cd3e was used as a control 
gene for normalization. For assays in patient specimens, absolute quantification of 
copies was conducted using standard curves generated with plasmid containing 
IL23A or IL12B cDNA.
TaqMan primers for the following genes were purchased from Applied 
Biosystems: human IL23A (assay ID Hs00372324_m1), human IL12B (assay ID 
Hs01011518_m1), human 18S RNA (assay ID Hs03003631_g1), human IL23R 
(assay ID Hs00332759_m1), human TBX21 (assay ID Hs00894392_m1), human 
RORC (assay ID Hs01076112_m1), human IFNG (assay ID Hs00989291_m1), 
mouse Il23a (assay ID Mm00518984_m1), mouse Il12b (assay ID Mm01288989_
m1), mouse Cd3e (assay ID Mm01179194_m1) and mouse Il23r (assay ID 
Mm00519943_m1).
SYBR Green primers for the following genes were purchased from Sigma:  
18S: forward, 5′-AACCCGTTGAACCCCATT-3′; reverse, 5′-CCATCCAATCGG 
TAGTAGCG-3′; SOX2: forward, 5′-ATAATAACAATCATCGGCGG-3′; reverse,  
5′-AAAAAGAGAGAGGCAAACTG-3′; SOCS3: forward, 5′-CCTATTACATCTA 
CTCCGGG-3′; reverse, 5′-ACTTTCTCATAGGAGTCCAG-3′; CEBPD: forward,  
5′-CAGACTTTTCAGACAAACCC-3′; reverse, 5′-TTTCGATTTCAAATGC 
TGC-3′; ABCA1: forward, 5′-GTGTTTCTGGATGAACCC-3′; reverse, 5′-TTCC 
ATTGACCATGATTGC-3′; IFIT1: forward, 5′-CTGCCTAATTTACAGCAACC-3′; 
reverse, 5′-TGATCCAAGACTCTGTTTTC-3′; IFIT3: forward, 5′-ATGAGTGA 
GGTCACCAAG-3′; reverse, 5′-CCTTGAAGTTCCAGGTG-3′; USP18: forward,  
5′-TGGTTTACACAACATTGGAC-3′; reverse, 5′-ATCCTCTTCAATATCCTGG 
TG-3′; CDKN2B: forward, 5′-GACTAGTGGAGAAGGTGC-3′; reverse, 5′-TCA 
TCATGACCTGGATCG-3′; HIF1A: forward, 5′-AAAATCTCATCCAAGAA 
GCC-3′; reverse, 5′-AATGTTCCAATTCCTACTGC-3′; EPAS1: forward, 5′-CAG 
AATCACAGAACTGATTGG-3′; reverse, 5′-TGACTCTTGGTCATGTTCTC-3′; 
BNIP3L: forward, 5′-AGGCATCTATATTGGAAAGC-3′; reverse, 5′-GCTTAC 
AATGGTCTCAAGTT-3′; PDK1: forward, 5′-ATGATGTCATTCCCACAATG-3′; 
reverse, 5′-AAGAGTGCTGATTGAGTAAC-3′; DDIT3: forward, 5′-CTTTTCCA 
GACTGATCCAAC-3′; reverse, 5′-GATTCTTCCTCTTCATTTCCAG-3′; DDIT4:  
forward, 5′-AATGTAAGAGTAGGAAGGGG-3′; reverse, 5′-ACAGTTCTAGAT 
GGAAGACC-3′; EGLN1: forward, 5′-CCCAAATTTGATAGACTGCTG-3′; 
reverse, 5′-ACACCTTTTTCACCTGTTAG-3′; EGLN3: forward, 5′-ATCATTCA 
TAGCAGATGTGG-3′; reverse, 5′-ATATCTGGTTGCGTAAGAGG-3′.
Immunoblot analysis. Protein was extracted from cells using RIPA buffer 
(Thermo) supplemented with proteinase and phosphatase inhibitors (Thermo). 
The same amount of protein for each sample was separated on precast 4–15% 
gradient gels (Bio-Rad) by SDS–PAGE and transferred to PVDF membranes  
(Bio-Rad). The membranes were blocked with 5% milk in TBS with 5% Tween-
20 and probed with primary antibodies at 4 °C overnight. Then, membranes 
were washed and incubated with secondary antibodies conjugated to HRP. 
The following primary and secondary antibodies were used: anti-IL-23R 
(Novus Biological; 1:1,000 dilution), anti-GAPDH (clone 6C5, Santa Cruz; 
1:1,000 dilution), anti-phospho-STAT3 (Tyr705) (clone D3A7, Cell Signaling 
Technology; 1:1,000 dilution), anti-phospho-STAT3 (Ser727) (clone 6E4, Cell 
Signaling Technology; 1:1,000 dilution), anti-STAT3 (clone D3Z2G, Cell Signaling 
Technology; 1:1,000 dilution), anti-CD3ζ (clone 6B10.2, Santa Cruz; 1:1,000  
dilution), goat anti-rabbit IgG-HRP (Santa Cruz; 1:3,000 dilution) and rabbit  
anti-mouse IgG-HRP (Santa Cruz; 1:3,000 dilution). Blot images were acquired 
with the ChemiDoc MP system (Bio-Rad), and densitometry was performed with 
Image Lab software (Bio-Rad).
Flow cytometry. For cell-surface staining, cells were incubated with antibodies at 
room temperature for 15 min or at 4 °C for 30 min. For intracellular staining, cells 
were fixed and permeabilized with Cytofix/CytoPerm (BD Biosciences) for 15 min 
at room temperature and washed with 1× PermWash (BD Biosciences). Subsequent 
staining was performed with 1× PermWash as the staining and wash buffer. For 
CellTrace Violet (CTV) staining, cells were labeled with 5 µM CTV (Thermo) 
before culture. In most assays, cells were stained with Zombie Aqua Live/Dead 
Discrimination dye (BioLegend) to exclude dead cells from analysis.
The following antibodies used for the flow cytometry analysis were obtained 
from BD Biosciences: APC-conjugated anti-CD4 (clone RPA-T4), FITC-conjugated 
anti-CD8 (clone RPA-T8), Alexa Fluor 700-conjugated anti-CD8 (clone RPA-
T8), PE-conjugated anti-IL-17A (clone SCPL1362), Alexa Fluor 647-conjugated 
anti-IFN-γ (clone B27), Alexa Fluor 647-conjugated anti-CD271 (NGFR; clone 
C40-1457), APC-conjugated anti-CD45RO (clone UCHL1), PE-conjugated 
anti-CD45RA (clone H100), PE-Cy7-conjugated anti-CD28 (clone CD28.2), 
BV421-conjugated anti-CD27 (clone M-T271), PE-Cy7-conjugated anti-CD279 
(PD-1; clone EH12.1), BV711-conjugated anti-Tim3 (clone 7D3), PE-conjugated 
anti-CD223 (LAG3; clone T47-530), Alexa Fluor 647-conjugated anti-Ki67 (clone 
B56), PE-conjugated Annexin V, 7AAD, PE-conjugated rat anti-mouse IgG1 (clone 
X56), APC-Cy7-conjugated anti-CD3 (clone SK7), PE-conjugated anti-granzyme B 
(clone GB11), PE-conjugated anti-CD101 (clone V7.1), PE-conjugated anti-TNF-α 
(clone MAB11), PE-conjugated anti-CD45 (clone HI30). FITC-conjugated rat anti-
mouse CD19 (clone 1D3), APC-Cy7-conjugated hamster anti-mouse CD3e (clone 
145-2C11), PE-conjugated rat anti-mouse Ly6G (clone 1A8), BV421-conjugated 
rat anti-mouse Ly6C (clone AL21), APC-Cy7-conjugated rat anti-mouse CD11b 
(clone M1/70), PerCP-Cy5.5-conjugated hamster anti-mouse CD11c (clone HL3), 
Peripheral blood, spleen and liver (the primary tumor site) were collected at the 
indicated time points to measure the expansion and persistence of infused T cells 
(hCD45+hCD3+) by flow cytometry.
For the orthotopic PDAC model, BXPC-3-Ffluc (1 × 105) tumor cells were 
suspended in 25 μl of DPBS, mixed with 25 μl of Matrigel (Corning) and surgically 
implanted into the pancreas of 8- to 10-week-old male NSG mice as previously 
described35. Fourteen days after tumor cell inoculation, control-vector-transduced 
T cells (Ctrl cells), B7-H3-specific CAR.Ctrl cells or CAR.p40-Td cells were 
injected intravenously via tail injection (2 × 106 cells per mouse). Tumor growth 
was monitored weekly by bioluminescence imaging using the IVIS Lumina II 
in vivo imaging system (PerkinElmer). In this model, engraftment does not 
induce lethality in mice even when they are left untreated for more than 8 weeks 
after T cell infusion. Mice were arbitrarily considered dead in survival analysis 
when the luciferase signal was at least 15-fold higher than the initial signal at 
week 0. All mice were killed at 8 weeks after T cell infusion, and peripheral blood, 
spleen and pancreas were collected to measure the persistence of infused T cells 
(hCD45+hCD3+) by flow cytometry.
Syngeneic mouse models. B16-OVA cells (5 × 105 cells per mouse) were suspended 
in 50 µl of DPBS mixed with 50 µl of Matrigel (Corning) and were subcutaneously 
injected into the left flank of 7- to 8-week-old male C57BL/6 mice. Seven days after 
tumor engraftment, WT or OT-1-TCR T cells were infused intravenously. Tumor 
size was monitored every 2–3 d after T cell infusion with a caliper. Tumor volume 
was calculated as length × width × width × 0.5, as previously described14, and mice 
with a volume >1,000 cm3 were killed and blood, spleen, tumor and tumor dLN 
were collected for immunophenotyping by flow cytometry.
For the orthotopic PDAC model, the mouse tumor cell line KPC-4662 was 
engineered to express mB7-H3 and implanted into the pancreas of 6-week-
old female C57BL/6J mice by surgery (1 × 105 cells per mouse). Eighteen days 
after tumor cell implantation, mice were irradiated with 400 cGy to create a 
lymphodepleted environment. Two days after irradiation, mice were infused 
intravenously with syngeneic T cells (1 × 107 cells per mouse). Tumor growth was 
monitored by ultrasound imaging biweekly. Some mice from the untreated group 
were killed at day 40 after tumor engraftment for immunohistochemistry staining 
of the TME.
Confocal microscopy. Cells were collected and divided equally into two groups. 
One group was stained with Alexa Fluor 594-conjugated mouse anti-GFP antibody 
(Thermo) and Alexa Fluor 647-conjugated anti-NGFR (BD Biosciences), while the 
other group was stained with Alexa Fluor 594-conjugated mouse anti-GFP antibody 
and Alexa Fluor 647-conjugated anti-CD19 antibody (Thermo). Cells were stained 
for 30 min at 4 °C and subsequently washed with ice-cold DPBS. Cells were then 
fixed with Cytofix (BD Biosciences) for 10 min at room temperature, washed with 
DPBS and loaded onto a glass slide using a Cytospin Cytocentrifuge (Thermo). 
Prolong Diamond Antifade Mountant with DAPI (Thermo) was applied before 
sealing the slide with a category 1.5 coverslip (Thermo). The slides were imaged 
using a Zeiss LSM710 microscope, and image data were analyzed with Fiji (ImageJ).
To quantify binding of p40–GFP fusion protein on the cell surface, 
the cell membrane was first defined on the basis of Alexa Fluor 647 signal 
(corresponding to anti-NGFR and anti-CD19 antibodies marking p40-Td and 
ΔCD19-Td cells, respectively). In parallel, an irrelevant area (either an area 
with no cells or intracellular space) was selected as a background area. The 
MFI of Alexa Fluor 594 signal (anti-GFP) was measured in the membrane and 
background areas, and the cell-surface binding of p40–GFP was calculated as 
MFI(membrane) – MFI(background).
Statistical analysis. Student’s t-tests were used to determine statistically significant 
differences between two samples. When multiple-comparison analyses were 
required, statistical significance was evaluated by ANOVA (one or two way), 
followed by Sidak’s post hoc analysis. If the data reflected measurement of one 
sample over time or under different conditions, repeated-measures ANOVA was 
used, followed by Sidak’s post hoc analysis. All statistical analyses were performed 
with two-tailed tests. Graph generation and statistical analyses were performed 
using GraphPad Prism, version 7 (GraphPad Software). A P value of less than 0.05 
was considered statistically significant.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq datasets generated and analyzed during the current study are not 
publicly available (the genetic information from primary human T cells in this 
study was not consented to be published in the public domain) and will be available 
from the corresponding authors upon request.
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PerCP-Cy5.5-conjugated rat anti-mouse CD4 (RM4-5), PE-conjugated rat anti-
mouse Vα2 TCR (clone B20.1) and FITC-conjugated rat anti-mouse Vβ5.1 5.2 TCR 
(clone MR9-4).
The following antibodies were obtained from Thermo: Alexa Fluor 
647-conjugated anti-CD19 (clone SJ25-C1) and Alexa Fluor 594-conjugated 
anti-GFP (polyclonal).
The following antibodies were obtained from BioLegend: BV711-conjugated 
rat anti-mouse CD45 (clone 30-F11), APC-conjugated rat anti-mouse CD8 (clone 
53-6.7), APC-conjugated rat anti-mouse CD64 (clone X54-5/7.1) and PE-Cy7-
conjugated rat anti-mouse F4/80 (clone BM8).
Flow cytometry data were collected on a BD LSRFortessa (BD Biosciences) 
using BD FACSDIVA software, and the flow data were analyzed with FlowJo 
software (v9.32, Tree Star).
Acquisition and processing of frozen patient tumor samples. Frozen patient 
tumor specimens and matching adjacent normal tissues were obtained from the 
Tissue Procurement Facility at the University of North Carolina at Chapel Hill. For 
RNA extraction, 20–30 mg of frozen tissues was lysed using RLT buffer from the 
RNeasy Plus kit (Qiagen). To extract extracellular protein in interstitial fluid for 
IL-23 ELISA, 40 mg of frozen tissue was incubated in DPBS to obtain a single-cell 
suspension and the supernatant was collected. Total protein amount was quantified 
by Bradford assay (Bio-Rad), and 100 µg of protein was used for ELISA.
RNA sequencing and GSEA. Total RNA was extracted as described above, and the 
library was prepared by the High-Throughput Sequencing Facility (HTSF) at the 
University of North Carolina at Chapel Hill using the KAPA Stranded mRNA-Seq 
kit (Kapa Biosystems). Twelve samples were pooled and sequenced using a HiSeq 
4000 (Illumina) with the high-output paired-end 50-bp setting (>20 × 106 reads 
per sample). Sequencing reads were aligned to the human genome (hg38) with 
the STAR aligner (v2.4.2)64 and subsequently quantified with Salmon (v0.8.2)65. 
Differential expression analysis was conducted with DESeq2 (v3.8)66 running 
on R (v3.5.0). Genes with log2 (fold change) > 1 and an FDR less than 0.05 in 
comparisons of Ctrl and p40-Td cells were considered to be significant.
For the PCA plot, genes with low expression (<20 counts across six samples 
(three for Ctrl cells and three for p40-Td cells)) were filtered out and data were 
transformed with regularized-logarithm transformation.
GSEA was performed with GSEA v2 software (Broad Institute)31 on genes 
that were differentially expressed between day 5 activated Ctrl and p40-Td cells. 
Gene sets specified in this study were as follows: DAUER_STAT3_TARGETS_UP 
(M12391): STAT3-upregulated genes67, DAUER_STAT3_TARGETS_DN 
(M13696): STAT3-downregulated genes67 and HALLMARK_HYPOXIA (M5891): 
genes upregulated in response to hypoxia.
Selected differentially expressed genes in the STAT3 or hypoxia pathways 
identified in RNA-seq were independently validated by qRT–PCR.
In vitro repetitive co-culture assays. Tumor cells (2.5 × 106; LAN-1, CHLA-255 
and BXPC-3, all labeled with GFP) were seeded in treated 12-well tissue culture 
plates for 24 h, after which 5 × 104 (effector to tumor (E:T)= 1:5) or 1.25 × 105 
(E:T = 1:2) CAR T cells were added to the tumor cells. After 3–5 d (accounting 
for donor variability in cytotoxicity), tumor cells had been completely eradicated 
(round 1). All cells in the well were collected and washed with PBS, resuspended 
in fresh medium and added to a new plate seeded with 2.5 × 106 tumor cells for 3 d 
(round 2). This procedure was repeated one more time, if applicable (round 3). At 
the end of each round, a duplicate well was collected for counting of residual tumor 
cells (GFP+) and CAR T cells (CD3+) and other phenotypic analysis (granzyme B, 
PD-1, CD101) of CAR T cells by flow cytometry.
For cytokine production assays after repetitive co-culture, 3 × 106 tumor cells 
(LAN-1) were irradiated with 40 Gy before seeding to reduce tumor burden for 
T cells, after which 1 × 105 (E:T = 1:3) CAR T cells were co-cultured with tumor 
cells in the assay.
Mouse experiments. Male and female 6- to 8-week-old NSG (NOD/SCID/IL-
2Rnull) mice were purchased from the Animal Core Facility at the University of 
North Carolina at Chapel Hill. Male and female 6- to 8-week-old C57BL/6J and 
OT-1 mice were purchased from the Jackson Laboratory. All mice were housed in 
the Animal Core Facility at the University of North Carolina at Chapel Hill. All 
mouse experiments were performed in accordance with UNC Animal Husbandry 
and Institutional Animal Care and Use Committee (IACUC) guidelines and were 
approved by the UNC IACUC.
Xenogeneic mouse models. For metastatic neuroblastoma models, CHLA-Ffluc 
(2 × 106) tumor cells were injected intravenously into 8- to 10-week-old female 
NSG mice. Two weeks later, mice were infused intravenously with GD2-specific 
CAR.Ctrl or CAR.p40-Td cells. Tumor progression was monitored weekly by 
bioluminescence imaging using the IVIS Lumina II in vivo imaging system 
(PerkinElmer). For re-challenge experiments, another dose of CHLA-Ffluc 
(3 × 106) cells was injected intravenously at 4 weeks after T cell infusion. Mice 
were killed when signs of discomfort were detected by the investigators or as 
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